CytomX - Model CX-188 - PD-1-Targeting Probody Therapeutic

CX-188 is our wholly owned PD-1-targeting Probody therapeutic. As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, CytomX has decided to indefinitely postpone the clinical trials of CX-188, a PD-1 Probody. CytomX may elect to initiate clinical trials of CX-188 in the future.